WIN-Partners Co., Ltd. (3183) Stock Price

Win Partners was established on April 1, 2013, through a management integration of Win International Co., Ltd. and Tesco Co., Ltd., serving as the complete parent company of both organizations. The company currently operates major bases primarily in the Greater Tokyo Area and Tohoku region, with plans for nationwide expansion.

Win Partners' business specializes primarily in the sales of medical devices. In the field of ischemic heart disease, the company provides medical devices such as catheters used in the treatment of myocardial infarction and angina. These devices are classified as "minimally invasive medical treatment," reducing patient burden.

In cardiac rhythm management, the company handles pacemakers and implantable cardioverter-defibrillators used in the treatment of arrhythmias. These devices enable the maintenance of normal cardiac rhythm.

In cardiovascular surgery, the company provides medical devices such as stent grafts and extracorporeal membrane oxygenation (ECMO) systems used in cardiac surgical procedures. These enhance the precision and safety of surgical treatment.

In peripheral vascular disease and neurosurgery, the company provides medical devices for treating peripheral vascular and cerebrovascular diseases. Specific products include PTA balloon catheters and peripheral vascular stents.

In medical imaging equipment, the company handles X-ray angiography systems, CT, MRI, and anesthesia machines used in radiology departments and operating rooms. These improve the precision of diagnosis and treatment.

Other medical devices provided include insulin pumps, continuous glucose monitoring systems, and blood pressure transducer sets. These serve as essential tools for supporting patient health management.

Win Partners operates under the corporate philosophy of "providing better quality of life to all people and contributing to the realization of a prosperous society." Based on this philosophy, the company aims to extend healthy life expectancy by promoting minimally invasive medical procedures. The company has adopted cost reduction in healthcare and the establishment of sustainable medical systems as its corporate mission, and is focusing on developing new demand and markets in response to advances in medical technology.

Win Partners aspires to be a leading company in next-generation healthcare-related businesses and seeks to maximize corporate value. Specifically, the company welcomes businesses that share its corporate philosophy into its group, promotes efficient allocation of management resources, and creates synergies. Additionally, the company is building fair and effective corporate governance while prioritizing trust-based relationships with stakeholders.

In the medical device sales industry, Win Partners places importance on ROE (return on equity) and targets 15.0% or higher in the medium term. The company is required to operate efficiently in response to heightened cost awareness among medical institutions and revisions to reimbursement prices. Through these efforts, the company aims for sustained growth.

Win Partners leverages its expertise in minimally invasive medical procedures and maintains a customer-centric approach. The company differentiates itself from competitors by offering tailored solutions across diverse needs, including cardiology, neurology, gastroenterology, and peripheral vascular disease. As Japan's aging population increases, demand for minimally invasive medical procedures is expected to grow, and the company is promoting their adoption and expansion.

Furthermore, Win Partners promotes industry consolidation through M&A and partnerships, expanding its sales areas and business domains. Through these initiatives, the company pursues sustained growth while developing new customers and deepening relationships with existing ones. The company accurately captures information on new medical technologies domestically and internationally, and works to introduce new products at an early stage.